In acute promyelocytic leukemia (APL), YOD1 raises the PML/RARa oncoprotein’s stability; therefore, a selective YOD1 inhibitor named ubiquitin isopeptidase inhibitor I (G5) may offer the chance to treat APL which is resistant to treatment [30]. This evidence concerns the gene YOD1 and acute promyelocytic leukemia.